Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast

Histopathology

Volumn 60, Issue 6, 2012, Pages 880-884

  Lee, Andrew H S ^a   Key, Heather P ^a   Bell, Jane A ^b   Hodi, Zsolt ^a   Ellis, Ian O ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Source Bioscience Plc   (United Kingdom)

Author keywords

Breast carcinoma; HER2; Immunohistochemistry; In situ hybridisation; Needle core biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST INVASIVE CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEEDLE CORE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA, NEOPLASM; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MASTECTOMY; RECEPTOR, ERBB-2; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84860282373     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04144.x     Document Type: Article

References (13)

1. Walker RA, Bartlett JM, Dowsett M et al. HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 2008; 61; 818-824.
2. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, Dowsett M. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann. Oncol. 2009; 20; 1948-1952.
3. Lee AHS, Key H, Bell J, Hodi Z, Ellis IO. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: the percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. J. Clin. Pathol. 2011; 64; 490-492.
4. Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod. Pathol. 2009; 22; 1151-1159.
5. D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am. J. Surg. Pathol. 2010; 34; 575-581.
6. Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am. J. Clin. Pathol. 2008; 129; 383-390.
7. Vincent-Salomon A, MacGrogan G, Couturier J et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 2003; 42; 337-347.
8. Andersson J, Linderholm B, Bergh J, Elmberger G. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 14-20.
9. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J. 2007; 13; 122-129.
10. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am. J. Clin. Pathol. 2005; 124; 273-281.
11. Chivukula M, Bhargava R, Brufsky A, Surti U, Dabbs DJ. Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Mod. Pathol. 2008; 21; 363-368.
12. Shin SJ, Hyjek E, Early E, Knowles DM. Intratumoral heterogeneity of HER-2/neu using fluorescence in-situ hybridisation and tissue microarray. Int. J. Surg. Pathol. 2006; 14; 279-284.
13. Hodi Z, Chakrabarti J, Lee AHS et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J. Clin. Pathol. 2007; 60; 299-302.